Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02294877 · ClinicalTrials.gov registry record
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- 418
- Enrollment target
NCT02294877 is a clinical trial that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 418 participants.
The verdict
NCT02294877 has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- 418 participants
- Enrollment target
Study Summary
The objectives of this program are: to characterize and describe the Mucopolysaccharidosis IV type A (MPS IVA) population as a whole, including the heterogeneity, progression, and natural history of MPS IVA; to evaluate the long-term effectiveness and safety of Vimizim®, including, but not limited to, the occurrence of serious hypersensitivity reactions, anaphylaxis, and changes in antibody status; to help the medical community with the development of recommendations for monitoring MPS IVA patients and reports on patient outcomes to optimize patient care; to collect data on other treatment paradigms, and evaluate the prevalences of their use and their effectiveness; to characterize the effects and safety of Vimizim treatment 5 years from enrollment in the Registry for patients under 5 years of age; to monitor pregnancy exposure, including maternal, neonatal, and infant outcomes; and to monitor patients who have completed the MOR-005 and MOR-007 clinical trials. These patients will be encouraged to enroll in the applicable Registry Substudy and will be monitored using the MOR-005 and MOR-007 assessment schedules, respectively.
Interventions
- DRUG Vimizim® (elosulfase alfa)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2014-09 |
| Est. Completion | 2024-02-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02294877
The ClinicalTrials.gov registry entry for NCT02294877 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vimizim® (elosulfase alfa) is the first listed.
NCT02294877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02294877 about?
NCT02294877 is a clinical study titled "A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)". The objectives of this program are: to characterize and describe the Mucopolysaccharidosis IV type A (MPS IVA) population as a whole, including the heterogeneity, progression, and natural history of MPS IVA; to evaluate the long-term effectiveness and safety of Vimizim®, including, but not limited t...
What is the current status of trial NCT02294877?
This trial is currently completed. The enrollment target is 418 participants. The study started on 2014-09. Estimated completion is 2024-02-21.
What interventions are being tested in trial NCT02294877?
The interventions under investigation include: Vimizim® (elosulfase alfa) (DRUG).
Who is sponsoring clinical trial NCT02294877?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.